<?xml version='1.0' encoding='utf-8'?>
<regulation prefix="Regulation" num=".11" citation="COMAR 10.50.01.11" title_num="10" subtitle_num="50" chapter_num="01" heading="Tissue Bank Standards — Testing to Minimize Disease Transmission.">
  <paragraph num="A.">
    <text>Required Testing.</text>
    <paragraph num="(1)">
      <text>General — All Donors. A permit holder shall ensure that a prospective donor of tissue, including both leukocyte-rich and leukocyte-poor cell and tissue, intended to be used as an allograft is tested for biochemical, immunological, or serological evidence of:</text>
      <paragraph num="(a)">
        <text>Hepatitis B virus (HBV);</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Hepatitis C virus (HCV);</text>
      </paragraph>
      <paragraph num="(c)">
        <text>Human immunodeficiency virus type 1 (HIV-1);</text>
      </paragraph>
      <paragraph num="(d)">
        <text>Human immunodeficiency virus type 2 (HIV-2); and</text>
      </paragraph>
      <paragraph num="(e)">
        <text>Treponema pallidum (syphilis).</text>
      </paragraph>
    </paragraph>
    <paragraph num="(2)">
      <text>Specific — Donors of Specific Tissue or Cell Types.</text>
      <paragraph num="(a)">
        <text>In addition to those tests set forth in §A(1) of this regulation, a permit holder shall ensure that a prospective donor of specific types of tissue are tested in accordance with the requirements set forth in §A(2)(b)—(c) of this regulation.</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Donors of Leukocyte-Rich Tissue. A permit holder shall ensure that a prospective donor of a leukocyte-rich tissue, as defined in Regulation .03B of this chapter, intended to be used as an allograft, is tested for biochemical, immunological, or serological evidence of:</text>
        <paragraph num="(i)">
          <text>Human T-lymphotropic virus type I (HTLV-I);</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Human T-lymphotropic virus type II (HTLV-II); and</text>
        </paragraph>
        <paragraph num="(iii)">
          <text>Cytomegalovirus (CMV).</text>
        </paragraph>
      </paragraph>
      <paragraph num="(c)">
        <text>Donors of Reproductive Tissue including Oocytes and Semen. In addition to those applicable tests set forth in §A(1) and (2)(a) of this regulation, a permit holder shall ensure that a prospective donor of reproductive tissue, as defined in Regulation .03B of this chapter, intended to be used as an allograft, is tested for biochemical, immunological, or serological evidence of:</text>
        <paragraph num="(i)">
          <text>Chlamydia trachomatis; and</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Neisseria gonorrhoeae.</text>
        </paragraph>
      </paragraph>
    </paragraph>
  </paragraph>
  <paragraph num="B.">
    <text>Required Laboratory Licensure.</text>
    <paragraph num="(1)">
      <text>In-House Testing Services. A tissue bank that conducts its own testing on human specimens shall possess a Maryland license to operate a medical laboratory and comply with all applicable standards as set forth in COMAR 10.10.01—10.10.08.</text>
    </paragraph>
    <paragraph num="(2)">
      <text>Contractual Testing Services. A tissue bank that contracts for laboratory testing services shall obtain and maintain:</text>
      <paragraph num="(a)">
        <text>The name and address of a contracted facility and documentation of the inclusive dates of the contract period; and</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Proof of the contracted facility's current:</text>
        <paragraph num="(i)">
          <text>Federal certification;</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Required State laboratory licensure; and</text>
        </paragraph>
        <paragraph num="(iii)">
          <text>Accreditation.</text>
        </paragraph>
      </paragraph>
    </paragraph>
    <paragraph num="(3)">
      <text>Other Testing Services. A tissue bank that obtains test results from a noncontracted laboratory, for example, another tissue bank or an organ retrieval organization, shall obtain and maintain the name, address, and licensing and accreditation information for each laboratory from which test results are obtained for the purpose of donor assessment.</text>
    </paragraph>
  </paragraph>
  <paragraph num="C.">
    <text>Confidentiality and Release of Test Results. A technical director of a tissue bank may release results of laboratory tests performed by the tissue bank holding a medical laboratory license or performed for the tissue bank by another licensed laboratory only:</text>
    <paragraph num="(1)">
      <text>To:</text>
      <paragraph num="(a)">
        <text>The medical director of the tissue bank;</text>
      </paragraph>
      <paragraph num="(b)">
        <text>An authorized person who requested the test; or</text>
      </paragraph>
      <paragraph num="(c)">
        <text>Another laboratory that requested the test as set forth under COMAR 10.10.06.04; and</text>
      </paragraph>
    </paragraph>
    <paragraph num="(2)">
      <text>As allowed under the:</text>
      <paragraph num="(a)">
        <text>Maryland Confidentiality of Medical Records Act, Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</text>
      </paragraph>
      <paragraph num="(b)">
        <text>Federal:</text>
        <paragraph num="(i)">
          <text>Health Insurance Portability and Accountability Act (HIPAA), 42 U.S.C. §§1320d et seq.;</text>
        </paragraph>
        <paragraph num="(ii)">
          <text>Health Information Technology for Economic and Clinical Health (HITECH) Act, 42 U.S.C. §§17921 et seq.; and</text>
        </paragraph>
        <paragraph num="(iii)">
          <text>Implementing rules and regulations for HIPAA and the HITECH Act set forth at 45 CFR Parts 160, 162, and 164.</text>
        </paragraph>
      </paragraph>
    </paragraph>
  </paragraph>
</regulation>